Plasma Cell Myeloma Clinical Trials

8 recruiting

Frequently Asked Questions

Common questions about Plasma Cell Myeloma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 21 trials

Recruiting
Phase 3

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Smoldering Plasma Cell Myeloma
ECOG-ACRIN Cancer Research Group288 enrolled707 locationsNCT03937635
Recruiting
Phase 3

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

RISS Stage I Plasma Cell MyelomaRISS Stage II Plasma Cell MyelomaPlasma Cell Myeloma
ECOG-ACRIN Cancer Research Group1,450 enrolled600 locationsNCT04566328
Recruiting
Phase 2

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Plasma Cell Myeloma Refractory
Sanofi64 enrolled34 locationsNCT06356571
Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Head and Neck CarcinomaMalignant Solid NeoplasmSarcoma+59 more
Alliance for Clinical Trials in Oncology2,000 enrolled740 locationsNCT05334069
Recruiting
Not Applicable

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Plasma Cell MyelomaRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma+1 more
Roswell Park Cancer Institute175 enrolled1 locationNCT05312255
Recruiting
Phase 1

A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

Plasma Cell Myeloma Refractory
Sanofi82 enrolled18 locationsNCT06630806
Recruiting
Phase 1

Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

Multiple MyelomaPlasma Cell Myeloma
Robert Flavell, MD, PhD20 enrolled1 locationNCT05892393
Recruiting

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

Hematopoietic and Lymphoid Cell NeoplasmLymphomaLeukemia+3 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT05011045
Recruiting
Phase 2

Personalized NK Cell Therapy in CBT

Acute Lymphoblastic LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic Leukemia+23 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT02727803
Recruiting
Phase 1

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
City of Hope Medical Center15 enrolled1 locationNCT05363111
Recruiting

Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma

Monoclonal Gammopathy of Undetermined SignificanceSmoldering Plasma Cell Myeloma
M.D. Anderson Cancer Center200 enrolled1 locationNCT02726750
Recruiting

Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

Monoclonal Gammopathy of Undetermined SignificanceSmoldering Plasma Cell Myeloma
M.D. Anderson Cancer Center400 enrolled1 locationNCT05136807
Recruiting
Phase 1

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Myelodysplastic SyndromeB-cell Non Hodgkin LymphomaRefractory Acute Myeloid Leukemia+16 more
Mayo Clinic127 enrolled2 locationsNCT03017820
Recruiting
Phase 2

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Smoldering Plasma Cell Myeloma
Emory University68 enrolled1 locationNCT04776395
Recruiting
Phase 2

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

Plasma Cell Myeloma
Emory University34 enrolled1 locationNCT05208307
Recruiting
Phase 1Phase 2

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Plasma Cell Myeloma Refractory
Sanofi258 enrolled27 locationsNCT04643002
Recruiting
Phase 2

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
City of Hope Medical Center29 enrolled1 locationNCT04508790
Recruiting
Not Applicable

Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

Bone PainMetastatic Malignant Neoplasm in the BonePlasma Cell Myeloma
University of Southern California100 enrolled9 locationsNCT03858205
Recruiting
Phase 3

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Plasma Cell Myeloma
SWOG Cancer Research Network510 enrolled397 locationsNCT05561387
Recruiting
Phase 1

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
City of Hope Medical Center30 enrolled1 locationNCT03710421